



## CELLUMEN APPOINTS DR. JACK A. REYNOLDS TO BOARD OF DIRECTORS

### *Pharmaceutical industry veteran brings more than 30 years of experience to Cellumen*

**Pittsburgh, PA, March 26, 2009** – [Cellumen, Inc.](#), a discovery toxicology company, today announced that industry veteran and former Pfizer executive Dr. Jack A. Reynolds has joined Cellumen’s [board of directors](#). With more than 30 years of experience in the pharmaceutical industry, Dr. Reynolds is founder and Principal at JAReynolds & Associates, which is focused on defining new paradigms for improving safety testing and decision making in the pharmaceutical industry.

“We are incredibly pleased to welcome Jack to our team,” says [D. Lansing Taylor](#), Ph.D., CEO of Cellumen. “He is highly regarded for his work in early safety testing, and we are confident that he will serve as a trusted advisor for the team at Cellumen, helping us to continue identifying safety liabilities earlier in the drug development process.”

Prior to his current role, Dr. Reynolds worked at Pfizer Global Research and Development for nearly 20 years, where he served as Senior Vice President of Research & Development and was head of Worldwide Safety Sciences and Comparative Medicine. He was instrumental in creating a Center for Molecular Safety Sciences at The Hamner Institutes for Health Sciences, and was the Interim Director of Safety Sciences and Translational Research.

In addition, Dr. Reynolds has been very active in industrial and professional activities in the areas of Safety Sciences and has served on the boards of the Health and Environmental Sciences Institute, Toxicology Education Foundation and the Toxicology Forum. Highly regarded by his peers, he was named the initial Chair of the Non Clinical Studies Advisory Committee of the Food and Drug Administration (FDA).

“Dr. Taylor has assembled an impressive collection of experts to serve on Cellumen’s board and I am honored to be joining their group,” says Dr. Reynolds. “Cellumen’s [CellCiphr®](#) technology echoes the initiatives that I have pursued throughout my career to revamp and improve pharmaceutical development through innovative solutions. I look forward to helping the company achieve future successes.”

Dr. Reynolds served as an Adjunct Clinical Professor in Comparative Medicine at Yale University and is currently an Adjunct Professor in the Division of Pharmacotherapy and Experimental Therapeutics, in the School of Pharmacy at the University of North Carolina at Chapel Hill.

Dr. Reynolds graduated Summa Cum Laude from Washington State University and completed a fellowship in Comparative Medicine and a residency in Comparative and Experimental Pathology at the Wake Forest Bowman Gray School of Medicine in Winston-Salem, N.C. He is certified by several specialty boards and is a Fellow of the International Academy of Toxicologic Pathologists. In 2004, Dr. Reynolds received a distinguished alumnus award for Teaching and Research from Washington State University.

#### **About Cellumen**

Cellumen is the leading collaborative partner and outsource service provider for the continuum of cell-based drug discovery and discovery toxicology solutions. Through its [CellCiphr® CSB™ Toxicity Profiling Services](#), Cellumen can predict the safest, most effective drugs in the drug discovery process, and as a result, reduce drug failure rates and cut development costs. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit [www.cellumen.com](http://www.cellumen.com).

#### **Cellumen Media Contact**

Theresa Murray

Gregory FCA

610-642-8253 x164

[Theresa@GregoryFCA.com](mailto:Theresa@GregoryFCA.com)